Cytoo raises €3.2M in second round funding

Funding round completed

Cytoo SA, a provider of technologies and products for high content cell analysis announced the closing of a second funding round of €3.2 million. New investor, Auriga Partners, led the round, with existing investor Jacques Lewiner, co-founder and president of the supervisory board at Cytoo, following on.

The Grenoble-based company will use the financing to grow its business internationally, expand the team and further its research and development.

“We are very pleased to support Cytoo as it enters a new phase in its development,” said Franck Lescure, partner at Auriga Partners. “With products already commercially available, and a promising technology, Cytoo is exactly the type of early-stage life sciences company with strong market potential that we look to finance.”

“Auriga Partners is a well-respected investor with an excellent reputation for working alongside early stage life science companies,” said François Chatelain, co-CEO at Cytoo. “Their participation in this round validates our business model and confirms the potential of our technology.”

Cytoo develops, manufactures and sells products that control internal cell organisation, thus making analysis more reliable. The company’s applications focus on cell-based assays, high-content analysis and cell screening. It has an exclusive worldwide licence from the Institut Curie and the CNRS, the French national scientific research centre, for the adhesive micropattern patent portfolio, as well as licence agreements with Harvard University and CEA, the largest government-funded technology research organisation in France.